Podcast: Just Listen to Nancy Reagan – Say NO to MDMA

This week’s podcast begins with a comment on the debate over ABA – helpful or harmful? But the big news this week is an analysis of very early, but very published, data on the use of MDMA, also known as “ecstasy” or “Molly”, in people with autism. Called an “empathogen”, MDMA can elicit feelings of warmth, love, and need to cuddle. However, it has a dark side. MDMA is a neurotoxin. It kills serotonergic brain cells. There is no known safe dose. Researchers studied and found weak evidence that it reduces social anxiety in people with autism. Social anxiety isn’t a core symptom of autism. Thank you to Dr. Larry Scahill of Emory University who provided an expert description of each condition. While ASF will not comment on every negative study out there, this one is worth noting.

When someone offers you MDMA, JUST SAY NO.

Researchers at Mount Sinai led by Alex Kolevzon are running a clinical trial of the compound insulin-like growth factor 1 (IGF-1) for children with idiopathic autism. Dr. Kolevzon’s team previously demonstrated the safety and feasibility of IGF-1 in treating Phelan-McDermid syndrome, a single-gene form of autism. Particularly, the IGF-1 treatment improved symptoms of social impairment and repetitive behaviors, which are core symptoms of autism. Expanding their investigation into idiopathic autism, the researchers are working hard to make sure families can comfortably and knowledgeably participate in the clinical trial. For this week’s podcast, Mahir Rahman spoke with Dr. Kolevzon about the study and where it hopes to go. Interested in joining the study? Go here to learn more.